ArticleJournal of general internal medicine2026
Polypharmacy Among Older Adults with Metabolic Dysfunction-Associated Steatotic Liver Disease.
Article in Journal of general internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMultimorbidity and polypharmacy are common in older adults with cardiometabolic diseases, but their burden in metabolic dysfunction-associated steatotic liver disease (MASLD) is less understood.
objectiveTo characterize multimorbidity and polypharmacy among older adults with MASLD.
designRetrospective cohort study.
participantsAdults ≥ 65 years with transient elastography data in NHANES 2017-2020. MAIN MEASURES: MASLD was defined as steatosis plus ≥ 1 metabolic risk factor; polypharmacy was ≥ 5 medications. Participants were stratified by age (65-69, 70-74, and ≥ 75 years). Survey-weighted analyses evaluated age and polypharmacy in MASLD and non-MASLD adults. Multivariable models adjusted for comorbidities. KEY
resultsAn estimated 42 million US adults ≥ 65 years were included, 39.8% had MASLD. The proportion of women with MASLD decreased with age (55.5 to 39.3%, p = 0.04). Diabetes, obesity, and cardiometabolic burden were higher in MASLD across all age groups (p < 0.01). Polypharmacy was most common in MASLD adults ≥ 75 years (60.3%), exceeding younger MASLD adults (36.9%, p = 0.002) and non-MASLD peers (42.7%; p = 0.005). MASLD adults had higher antidiabetic but lower antihypertensive use (p < 0.05). MASLD adults ≥ 75 years had over three times the odds of polypharmacy versus those 65-69 years (aOR 3.12, 95%CI 2.21-4.42).
conclusionsOlder adults with MASLD ≥ 75 years face a significant and independent burden of polypharmacy. This challenge is especially salient in MASLD, where aggressive management of cardiometabolic comorbidities is essential to preventing disease progression and non-liver mortality, yet the medications used may heighten geriatric vulnerabilities. Age-appropriate medication review, deprescribing, and goal concordant care are critical to navigating this tension in this high-risk population.
Indexed as
Identifiers
42448928What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.